help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Julien, S.
Right arrow Articles by Depierre, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Julien, S.
Right arrow Articles by Depierre, A.
The Oncologist, Vol. 5, No. 2, 115-119, April 2000
© 2000 AlphaMed Press

Non-Small Cell Lung Cancer: A Study of Long-Term Survival after Vinorelbine Monotherapy

S. Julien, P. Jacoulet, A. Dubiez, V. Westeel, A. Depierre

Service de Pneumologie, CHU Jean Minjoz, Besançon, France

Correspondence: Pr A. Depierre, Service de Pneumologie, CHU Jean Minjoz, 25030 Besançon, France. Telephone: 33-3-81-66-88-02; Fax: 33-3-81-66-88-13; e-mail: pneumo-depierre{at}ufc-chu.univ-fcomtc.fr

This study reports the results of 120 patients with inoperable non-small cell lung cancer treated with Navelbine at a dose of 25-30 mg/m2/week in a single-drug chemotherapy regimen. Surgery was contraindicated due to staging or to concomitant morbidity. Twenty patients achieved survival greater than or equal to 18 months, and one patient obtained exceptional survival of more than 120 months. The mean dose intensity of Navelbine in long-term survivors was 21.61 mg/m2/week. Objective response to Navelbine was found by multivariate analysis to be a prognostic factor for survival beyond 18 months. Weight loss of more than 5 kg of corporal weight was an unfavorable prognostic factor in patients with metastatic disease.

Key Words. Non-small cell lung cancer • Chemotherapy • Vinorelbine • Prognostic factor • Survival




This article has been cited by other articles:


Home page
 The OncologistHome page
C. Gridelli
The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
Oncologist, February 1, 2001; 6(2008): 4 - 7.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2000 by AlphaMed Press.